Oncodesign Société Anonyme

ENXTPA:ALONC Stock Report

Market Cap: €99.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Oncodesign Société Anonyme Valuation

Is ALONC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALONC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALONC (€14.42) is trading below our estimate of fair value (€215.74)

Significantly Below Fair Value: ALONC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALONC?

Key metric: As ALONC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALONC. This is calculated by dividing ALONC's market cap by their current revenue.
What is ALONC's PS Ratio?
PS Ratio3x
Sales€32.67m
Market Cap€99.44m

Price to Sales Ratio vs Peers

How does ALONC's PS Ratio compare to its peers?

The above table shows the PS ratio for ALONC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.7x
ALNOV Novacyt
2xn/a€44.1m
TNG Transgene
16.7x2.9%€108.8m
OSE OSE Immunotherapeutics
2.4x-45.1%€201.2m
ALERS Eurobio Scientific Société anonyme
1.8x3.9%€258.6m
ALONC Oncodesign Société Anonyme
3x14.7%€99.4m

Price-To-Sales vs Peers: ALONC is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (23.1x).

Price to Sales Ratio vs Industry

How does ALONC's PS Ratio compare vs other companies in the FR Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
ALGEN genOway Société anonyme
1.1xn/aUS$33.35m
LYS Lysogene
0.4xn/aUS$5.42m
ALINT IntegraGen
0.2xn/aUS$3.27m
GV Genomic Vision Société Anonyme
0.4xn/aUS$746.33k
ALONC 3.0xIndustry Avg. 4.4xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ALONC is good value based on its Price-To-Sales Ratio (3x) compared to the French Biotechs industry average (4.2x)

Price to Sales Ratio vs Fair Ratio

What is ALONC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALONC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3x
Fair PS Ratio3.4x

Price-To-Sales vs Fair Ratio: ALONC is good value based on its Price-To-Sales Ratio (3x) compared to the estimated Fair Price-To-Sales Ratio (3.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALONC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€18.64
0%
18.0%€22.00€15.29n/a2
Nov ’25n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Oct ’25n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Sep ’25n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Aug ’25n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Jul ’25n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Jun ’25n/a
€18.64
0%
18.0%€22.00€15.29n/a2
May ’25n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Apr ’25n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Mar ’25n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Feb ’25n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Jan ’25n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Dec ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Nov ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Oct ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Sep ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Aug ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Jul ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Jun ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
May ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Apr ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Mar ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Feb ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Jan ’24n/a
€18.64
0%
18.0%€22.00€15.29n/a2
Dec ’23€14.44
€16.67
+15.5%
18.5%€22.00€14.40n/a4
Nov ’23€14.32
€16.67
+16.4%
18.5%€22.00€14.40n/a4

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Sanofi

€118.3b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€94.40

7D

-1.4%

1Y

11.3%

Eurofins Scientific

€8.7b

Provides various analytical testing and laboratory services worldwide.

ERF

€46.17

7D

1.5%

1Y

-12.0%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

7D

-0.4%

1Y

-56.6%